English

CGTN:How do stable China-Russia ties contribute to a turbulent world?

BEIJING, May 08, 2025 (GLOBE NEWSWIRE) — A natural gas pipeline that stretches 3,000 kilometers in Russia and 5,111 km in China commenced operations in December last year, benefiting about 450 million people along its route. The China-Russia east-route natural gas pipeline is a landmark project of energy cooperation between the two countries, yet ties […]

EAACI Hong Kong Allergy School 2025: A Landmark in Global Allergy Education

ZURICH, May 08, 2025 (GLOBE NEWSWIRE) — The European Academy of Allergy & Clinical Immunology (EAACI), in partnership with the Hong Kong Institute of Allergy (HKIA), is proud to announce the inaugural EAACI Hong Kong Allergy School. This significant milestone will unfold in Hong Kong – Asia’s World City – a dynamic hub where East […]

Nyxoah to Release First Quarter 2025 Financial Results on May 14, 2025

Nyxoah to Release First Quarter 2025 Financial Results on May 14, 2025 Mont-Saint-Guibert, Belgium – Wednesday May 7, 2025, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the Company will release financial results for the first quarter of 2025 […]

Your World empowers young people to become leaders and agents of change

This year’s national winners from Royal International School, Kurunegala in Sri Lanka focused on a new initiative at their school, enabling students to benefit from outdoor learning. The first and second runner-up winners, selected from the national entries, were Brisbane International School and Musaeus College. On a global scale, 642 entries were submitted by 3,210 students from […]

Dr. Falk Pharma announces positive results from its pivotal phase 3 trial on norucholic acid in primary sclerosing cholangitis

Freiburg, May 7th, 2025 Study results demonstrate superiority of norucholic acid (NCA) over placebo in the combined primary endpoint. There is currently no approved medicine to treat primary sclerosing cholangitis. The results of the 96-week analysis of the NUC-5 trial will be presented at 2025 EASL Congress in Amsterdam. Dr. Falk Pharma, a research-based pharmaceutical […]